emjreviews.com
Cure8 news brief
Interview: Nuru Noor
Research and clinical trials
Infliximab
Anti-TNF
Phase 3 clinical trial
Clinicians
Researchers
Patients On Biologics
Newly Diagnosed
Why This Matters
The 5-year PROFILE follow-up is presented as strong evidence that early, effective therapy (in this case infliximab plus an immunomodulator) can change the long-term course of Crohn’s disease by lowering surgery rates and progression to complicated disease—findings that could affect how clinicians and patients decide about starting advanced therapy at diagnosis.
Who Should Pay Attention
Newly diagnosed Crohn’s patients (moderate–severe), clinicians treating IBD, researchers and trialists, and patients considering early biologic therapy
Study Snapshot
Story typeResearch news
Evidence typePhase 3 clinical trial
Source depthFull source text
What To Know
The interview with Dr Nuru Noor summarizes PROFILE’s long-term findings and places them in context.
PROFILE used an early “top-down” strategy with intravenous infliximab plus an immunomodulator started soon after diagnosis and found sustained benefits at 5 years across objective disease-modification outcomes (fewer abdominal surgeries, less progression to complicated phenotypes, fewer hospital admissions).
The piece also discusses the IOIBD consensus definition of disease modification and contrasts explanatory commercial trials with pragmatic, adaptive, and platform trial designs that may better answer real-world clinical questions.
Keep In Mind
This is an interview summarizing published trial follow-up and expert interpretation. For numeric details, eligibility, and absolute effect sizes, consult the original PROFILE publications and clinical guidelines. The article also discusses trial-design approaches (pragmatic, adaptive, Bayesian/platform trials) rather than reporting new trial results for those designs.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationemjreviews.com
AuthorsMolly Edwards
Indexed viaBing News
Source typeWeb article
PublishedSep 7, 2026, 5:00 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
'Top-down' therapy linked to fivefold lower risk for abdominal surgery in Crohn's disease
Early “top-down” infliximab plus an immunomodulator was linked to much lower 5-year risk of abdominal surgery, disease progression, and hospitalization versus a step-up approach. This could influence treatment planning...
Autologous Stem Cell Transplant for Crohn's Disease
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...